Analyst Expectations For Immunocore Hldgs's Future
Portfolio Pulse from Benzinga Insights
Immunocore Holdings (NASDAQ:IMCR) has been analyzed by 7 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $82.86, with a high of $100 and a low of $66. Recent evaluations show a decline in the average price target from $87.29. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Immunocore is a biotechnology company focused on TCR bispecific immunotherapies, with significant revenue from the US. Despite a positive revenue growth rate of 26.18%, the company faces challenges with a high debt-to-equity ratio and negative net margin.
September 17, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immunocore Holdings has received mixed analyst ratings, with a current average price target of $82.86, down from $87.29. Analysts have adjusted their ratings and price targets, reflecting market dynamics and company performance. The company shows positive revenue growth but faces challenges with high debt and negative margins.
The mixed analyst ratings and adjustments in price targets indicate uncertainty in the short-term performance of IMCR. While the company shows positive revenue growth, the high debt-to-equity ratio and negative net margin present financial challenges. These factors contribute to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100